Abstract-Cardiac angiotensin-converting enzyme (ACE) may play an important role in regulating cardiac hypertrophy.
T he pathogenesis of cardiovascular diseases such as hypertension, atherosclerosis, and myocardial infarction involves a process of cardiac remodeling associated with increased local expression of biologically active substances that are postulated to play pathophysiological roles. In hypertension, the heart undergoes a process of cardiac hypertrophy that is associated with the activation of a local angiotensin system (the renin-angiotensin system [RAS]). [1] [2] [3] The potential role of autocrine/paracrine mediators such as angiotensin in cardiovascular pathobiology independent from systemic factors has been suggested from indirect evidence: cell culture studies, morphological analysis, and/or systemic administration of antagonists and agonists. To elucidate the role of a specific autocrine/paracrine factor, we have developed an efficient in vivo gene transfer technique to examine the consequences of overexpression of the factor in local tissues in the intact rat. Using this approach, we had previously reported that transfection of human angiotensin-converting enzyme (ACE) into local segment of the carotid artery resulted in vascular hypertrophy independent of the circulating RAS and hemodynamics. 4 This approach is particularly powerful because the locally transfected vessel segment can be compared with adjacent untransfected segments as well as the contralateral vessel. Furthermore, the transfected segment is exposed to the same blood pressure and circulating factors as the control vessel. However, the role of ACE within the heart still remains unclear, because it is very difficult to transfect efficiently into cardiac myocytes in vivo. To overcome these issues, we reported a high transfection efficiency with the hemmaglutinating virus of Japan (HVJ, or Sendai virus) liposome method into intact rat hearts. [5] [6] [7] For example, luciferase activity was significantly higher in intact noninfarcted hearts transfected with the luciferase vector by the HVJ liposome method than in intact noninfarcted hearts transfected by direct injection of "naked" plasmid DNA. 6 Using this method, we further examined the role of autocrine/ paracrine angiotensin as a mediator of cardiac hypertrophy in vivo in this study.
Previous data have demonstrated that angiotensin II (Ang II) can stimulate the protein contents of cardiac myocytes and modulate extracellular matrix. 8 -11 Ang II is generated via an enzymatic cascade in which tissue ACE plays a key role. 12, 13 We postulate that increased cardiac ACE expression induces cardiac hypertrophy via increased local generation of Ang II within the heart. Our results provide the first direct evidence that overexpression of an autocrine/paracrine factor (ie, angiotensin) transfected into the heart in vivo mediates the cardiac remodeling process of hypertension independent of systemic factors or hemodynamic stimuli. In this study, we tested our hypothesis by (1) transfecting the human ACE vector locally into intact rat hearts in vivo and (2) studying the biochemical and physiological consequences of overexpression of ACE within the hearts. Our data demonstrate that increased local expression of ACE within the heart promotes autocrine/paracrine Ang II-mediated cardiac hypertrophy in vivo.
Methods

Construction of Plasmids
The pUC-CAGGS expression vector plasmid (kindly provided by Junichi Miyazaki, Tokyo University, Tokyo, Japan) 14 was digested with EcoRI. The EcoRI fragment containing the human truncated ACE vector of RB 35-15, including 2 putative active sites, was inserted into the EcoRI site in this vector by filling EcoRI ends with T4 polymerase. 4, 15 CAGGS contains the entire envelope region open reading frame consisting of 3 translation initiation codons, which represent the N-termini of the large, middle, and major surface (S) polypeptides downstream of the cytomegalovirus enhancer and the chicken ␤-actin promoter. The vector used as a control was pUC-CAGGS, which did not contain the ACE cDNA. The luciferase gene expression vector is driven by the Epstein-Barr virus (EBV) promoter or ␤-actin promoter. 16 
Preparation of HVJ Liposomes
The preparation of conventional HVJ liposomes has been described previously. 4, 6, 17, 18 In brief, phosphatidylserine, phosphatidylcholine, and cholesterol were mixed in a weight ratio of 1:4.8:2. The lipid mixture (10 mg) was deposited on the sides of a flask by removal of tetrahydrofuran in a rotary evaporator. Dried lipid was hydrated in 200 L of balanced salt solution (137 mmol/L NaCl, 5.4 mmol/L KCl, and 13 mmol/L Tris-HCl, pH 7.6) containing the DNA-highmobility group-1 complex (300 g:96 g), which had previously been incubated at 20°C for 1 hour. Liposomes were prepared by shaking and sonication. Purified HVJ (Z strain) was inactivated by UV irradiation (110 erg ⅐ mm Ϫ2 ⅐ s Ϫ1 ) for 3 minutes just before use. The liposome suspension (0.5 mL, containing 10 mg of lipids) was mixed with HVJ (20 000 hemagglutinating units) in a total volume of 4 mL of balanced salt solution. The mixture was incubated at 4°C for 10 minutes and then for 30 minutes with gentle shaking at 37°C. Free HVJ was removed from the HVJ liposomes by sucrose density gradient centrifugation. The top layer of the sucrose gradient was collected for use. Cationic HVJ liposome were made by phosphatidylcholine, cholesterol, and cholesteryl N-(dimethylaninoethyl)-carbamate mixed in a weight ratio of 8:4:1. 16, 19 In Vivo Gene Transfer Into the Heart by the Direct Injection Approach Male Sprague-Dawley rats (400 to 500 g; Charles River Breeding Laboratories, Boston, MA) were anesthetized with an intraperitoneal injection of sodium pentobarbital (0.1 mL/100 mg body weight). Rats were intubated and connected to a respirator. HVJ-liposome complex containing human ACE or the control vector was carefully injected directly into the heart with a 30-gauge needle through a left lateral thoracotomy into multiple sites. One injection volume of HVJ-liposome complex was 10 L (0.2 g of plasmid). [5] [6] [7] These experiments were approved by the Osaka University Animal Use Committee.
Administration of ACE Inhibitor (Perindopril)
Before transfection, rats received Alzet minipumps (Alza Inc) implanted intraperitoneally. Untreated animals received vehicle (1:1, vol/vol, of saline/polyethylene glycol 400), whereas the treated groups received the ACE inhibitor (perindopril, generously donated by Daiichi Pharmaceutical Company, Tokyo, Japan) at a dose of 10 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 . This administration regimen had previously been demonstrated to block the effects of Ang II in vivo. 20, 21 The drugs were administered immediately after transfection with human ACE or the control vector and continued until the hearts were harvested for morphometry.
Measurement of ACE Activity
For the measurement of cardiac ACE activity, rats were killed 3 days after transfection. After infusion of PBS, the hearts were removed and immediately frozen in LN 2 . On the day of assay, the hearts were thawed, weighed, and homogenized in 50 mmol/L KPO 4 (pH 7.5). ACE activity, expressed as hippuryl-L-histidyl-L-leucine hydrolyzing activity of the homogenate, was determined by the modified method of Cushman and Cheung. 22 Cardiac ACE activity was normalized by expressing activity per milligram of tissue. The specificity of ACE activity was previously confirmed by its complete inhibition by either quinaprilat (a specific ACE inhibitor) or neutralizing antibodies to ACE, as previously described. 4, 23 
Histological Analyses
For morphological analyses, rat hearts were removed 2 weeks after transfection, after perfusion-fixation with 10% formaldehyde under physiological pressure (110 mm Hg). The thickness and area of cardiac myocytes were measured on a digitizing tablet (model 2200, South Micro Instruments) after the tissue was stained with hematoxylin. At least 5 individual sections from the hearts were analyzed to avoid the effects of needle injection, as the area of transfection could be detected throughout the myocardium owing to the multiple injection sites for the HVJ liposome method. 6, 7 Animals were coded so that the analysis was performed without the investigator's knowledge of which treatment each animal had received. Histological analysis was performed by using a computerized morphometry system (Nexus 6400, Kashiwagi Research Co) by individuals who were unaware of the treatment each animal had received. The reproducibility of the results was assessed. Intraobserver variability was determined from triplicate measurements performed by 1 observer for all sections. The meanϮSD differences among measurements made by the same observer was 2.2Ϯ0.4%. Interobserver variability was determined from measurements of 10 randomly selected sections performed by a second observer in addition to the first observer. The difference between measurements made by the 2 observers was 3.3Ϯ0.4%. These observers were blinded to other data concerning the rats, as well as to the results of the other observer.
Sirius Red Method for Collagen Staining
Sirius red microscopy detects interstitial collagen, including types I and III. 24 Fresh-frozen sections (6 m) were rinsed with distilled water and incubated with 0.1% Sirius red F3BA (Polyscience Inc) in saturated picric acid for 90 minutes. Sections were rinsed twice with 0.01N HCl for 1 minute and then immersed in distilled water. After dehydration with 70% ethanol for 30 seconds, sections were coverslipped. The stained sections were observed under polarized light and photographed with the same exposure time for each section. Analysis of Sirius red staining was performed with a computer-based quantitative color image analysis system. 25 Photographs were scanned into a 1Kϫ1K image buffer of the Optimas 5.2 image analysis system (Optimas Co). A color threshold mask for immunostaining was defined to detect the red color by sampling, and the same threshold was applied to all specimens. The percentage of the total area with positive color for each section was recorded.
Analysis of Luciferase Activity
Firefly luciferase activity was measured by using a luciferase assay system (PicaGene, Toyo-Inki). Rats were killed 4 days after transfection with the luciferase gene either by direct transfection of "naked" plasmid or by the HVJ-liposome method via direct injection into the apex, as described below. The tissue samples (200 mg around the injection site) were rapidly frozen in LN 2 and homogenized in a lysis buffer. The tissue lysates were briefly centrifuged (3000 rpm, 10 minutes), and 20 L of supernatant was mixed with 100 L of luciferase assay reagents. Measurements of the luminescent reaction were started 5 seconds after addition of the sample. The counting lasted for 10 seconds, and the number of counts in 10 seconds was used for calculation of luciferase activity. 6 
Statistical Analysis
All values are expressed as meanϮSEM. ANOVA with Duncan's test was used to determine the significance of differences in multiple comparisons. PϽ0.05 was considered to be statistically significant.
Results
Overexpression of Cardiac ACE
To evaluate the success of gene transfer, we initially measured cardiac ACE activity. The biological activity of the transgene product was documented by a 2-fold increase in ACE activity within ACE-transfected hearts (Figure 1) . Given that the administration of ACE inhibitors or Ang II receptor antagonists resulted in the improvement of cardiac hypertrophy in hypertension, we hypothesized that increased local production of ACE would modulate cardiac structure. Therefore, we performed morphological studies 2 weeks after transfection. Evidence of local cardiac hypertrophy after ACE gene transfer persisted for at least 2 weeks after transfection, as reflected by the increasing thickness and area of cardiac myocytes ( Figure 2 ) and the increasing cardiac protein content in ACE vector-transfected hearts compared with controls. Interestingly, administration of the ACE inhibitor perindopril inhibited the cardiac hypertrophy induced by the local overexpression of ACE (Figure 2a) . Morphometric analysis documented that the thickness of ACE transfectedhearts was significantly increased compared with control vector-transfected and untransfected hearts (Figure 2b) . Consequently, the area of cardiac myocytes in ACE-transfected hearts was significantly greater than that of control vectortransfected hearts (Figure 2c ). However, there were no discernible differences in cell numbers counted in serial sections of the hearts between ACE-transfected and control vector-transfected hearts (data not shown). Furthermore, we evaluated the effects of ACE overexpression on collagen synthesis, as Ang II is well known to stimulate collagen synthesis, and the accumulation of collagen matrix deposition is a typical feature of hypertensive cardiac hypertrophy. We performed Sirius red staining for collagen, as Sirius red staining when viewed under polarized light identifies collagen, including types I and III. 24 Hearts transfected with control vector showed positive Sirius red staining near the injection sites only, demonstrating a low content of interstitial collagen at baseline (Figure 3 ). In contrast, hearts transfected with ACE vector exhibited substantial accumulation of interstitial collagen around the injection site (Figure 3 ). Of importance, transfection of the human ACE vector into intact hearts resulted in a significant increase in collagen matrix compared with control vector, as assessed by quantitative color image analysis (PϽ0.01, Figure 3) . Importantly, these cardiac changes are independent of the circulating RAS or hemodynamic changes such as blood pressure, heart rate, and serum ACE activity (Table 1) . Moreover, the morphometric changes typical of cardiac hypertrophy induced by ACE overexpression were also abolished by administration of the ACE inhibitor perindopril. These results revealed that cardiac-specific transfection produced a novel animal model overexpressing cardiac ACE without interference from the circulating RAS or hemodynamic changes, such as blood pressure, heart rate, and serum ACE activity.
Comparison of Transfection Efficiency
Given the successful production of a novel cardiac hypertrophy model, we further modified the gene transfer techniques with the HVJ liposome method. First, comparison of the expression of different kinds of promoter was evaluated. We constructed a luciferase expression vector driven by the ␤-actin promoter or the EBV promoter, as the EBV promoter prolongs transgene expression. 16 Consistent with previous findings, luciferase activity was markedly increased in hearts transfected with the luciferase vector driven by ␤-actin and using the HVJ liposome method compared with that produced by direct injection (PϽ0.01, Figure 4) . Consistent with the previous observation that the EBV promoter increases the amount of expressed protein, 16 our study showed a significant increase in luciferase activity in hearts transfected with the luciferase construct driven by EBV promoter compared with the ␤-actin promoter 4 days after transfection. Moreover, we also modified the HVJ liposome method by changing the composition of the lipid. In this study, we modified the liposomes from the anionic to the cationic type, as previous reports had mentioned that the cationic liposome HVJ liposome method is more efficient for transfection in vitro as well as in vivo into various tissues compared with the conventional (anionic) HVJ liposome complex (see Figure 5a) . 16, 19 Thus, we examined luciferase expression by using the conventional HVJ liposome complex and the cationic HVJ liposome method for transfection into hearts. Unexpectedly, luciferase activity was very low in hearts transfected with the luciferase vector driven by ␤-actin promoter and using cationic HVJ liposomes, whereas high luciferase activity was observed with the conventional (anionic) composition (Figure 5b ).
Discussion
Cardiovascular hypertrophy is thought to be an adaptive response to hypertension. Although it is well accepted that the mechanical effects of increased blood pressure stimulate cardiac and/or vascular hypertrophy, recent indirect evidence suggests that humoral factors may also play an important role. Ang II can stimulate the protein contents of cardiac myocytes and influence extracellular matrix. 8 -11 In vivo data from experimental animals have provided additional support for a direct Ang II contribution. 26 -29 A key enzyme in the reninangiotensin biochemical cascade is ACE, which is expressed diffusely in cardiovascular organs such as the heart and blood vessels. [1] [2] [3] 12, 13 It has been stated that ACE is not rate limiting in Ang II production, since its total quantity in the body is high. However, several investigators have reported that in vivo increases in local cardiac ACE activity in experimental animals result in parallel increases in tissue Ang I conversion to Ang II and changes in local function. 8, 26 Indeed, it is reported that pressure-overload cardiac hypertrophy induced by aortic banding induces cardiac ACE gene expression and increased cardiac Ang II production. 28 Nevertheless, 2 important questions have not yet been resolved in hypertension and cardiovascular research. First, can the RAS directly mediate cardiac hypertrophy, independent of its blood pressure effect? Second, is local tissue ACE important in regulating local cardiovascular function and in contributing to pathophysiology? To answer these questions, we previously employed in vivo gene transfer technology, since these questions have only been addressed indirectly by evidence derived from in vitro cell culture studies, in vivo systemic infusion of Ang II, and/or administration of ACE inhibitors. 1-3,26 -29 In vivo gene transfer technology has the following advantages: (1) the target gene can be transfected into a Figure 4 . Transfection of luciferase vector driven by the ␤-actin or the EBV promoter to the hearts. PBS indicates injected with PBS (n ϭ3); control, control vector-transfected hearts by the HVJ liposome method (nϭ6); direct, transfection of naked luciferase plasmid driven by the ␤-actin promoter without the HVJ liposome method (n ϭ6); ␤-actin, transfection of luciferase plasmid driven by the ␤-actin promoter with the HVJ liposome method (n ϭ6); EB, transfection of the luciferase plasmid driven by the EBV promoter with the HVJ liposome method (nϭ6). **PϽ0.01 vs control, ##PϽ0.01 vs direct. Figure 5 . a, Modification of lipid composition of the HVJ liposome method. Conventional the HVJ-anionic liposome complex is not easy to attach to the cell surface owing to the anionic charge of cellular membranes. In contrast, the HVJ-cationic liposome complex may be easily attached to the cellular surface, potentially resulting in a higher transfection efficiency. b, Transfection of luciferase vector driven by the ␤-actin promoter to the hearts by using the conventional or cationic HVJ-liposome complex HVJ liposome indicates transfection of the luciferase vector by the conventional (anionic) HVJ-liposome method (n ϭ4); HVJ-cationic liposome, transfection of the luciferase vector by the cationic HVJ-liposome method (nϭ6).
local segment, thereby avoiding a systemic effect, and (2) the consequences of local overexpression within the physiological/pathophysiological range of the target gene may be studied. Indeed, luciferase activity was detected in the myocardium only by transfection of the luciferase vector by the HVJ liposome method, whereas luciferase activity was not detected in other tissues (brain, lung, liver, kidney, and testis; M.A. et al, unpublished observations, 1996). In contrast, none of these data are completely convincing owing to the contribution of confounding variables such as hemodynamic effects, cell culture conditions, etc. Indeed, our previous study could demonstrate direct evidence of the contribution of vascular ACE in the pathogenesis of vascular hypertrophy. 4 However, none of the other reports provided direct evidence of the involvement of cardiac ACE in the pathogenesis of cardiac hypertrophy.
In this study, we have extended our investigation to ACE gene transfer in vivo into rat hearts. We were able to study the long-term cardiac effects of increased tissue ACE activity. As previously reported, HVJ liposome-mediated gene transfer is an efficient in vivo method that has minimal or no toxicity and provides sustained gene expression for transfection into hearts. [5] [6] [7] Moreover, the present study confirmed the high transfection efficiency of the HVJ liposome method by using 2 different kinds of luciferase construct. Although transgenic technology also provides the opportunity to study specific gene function, this technology has several disadvantages: (1) it is time consuming and costly, (2) the effect of the overexpressed transgene is exerted throughout development, and (3) it is difficult to exclude a potential contribution of the systemic effect of transgene expression. Previous studies have documented the roles of hemodynamic stimuli and systemic neurohumoral factors in cardiac hypertrophy in hypertension. 3, 12, 13, 28 The present study documents for the first time that the hypertensive cardiac structural response can be mediated by locally generated factors within the heart. Our study supports the notion that ACE is a key rate-limiting enzyme governing Ang II production in cardiac tissues. The increased local expression of ACE is sufficient to induce Ang II-mediated cardiac hypertrophy, independent of changes in the circulating RAS and hemodynamics. This observation is consistent with previous morphometric analyses of hypertensive hearts documenting hypertrophy. 30, 31 Ang II has been reported to induce the expressions of proliferative factors such as fibroblast growth factor and platelet-derived growth factor, as well as factors influencing the extracellular matrix, such as transforming growth factor-␤. 1, 11, 12 Therefore, myocyte-derived transforming growth factor-␤ induced by increased Ang II within the heart may promote the production of extracellular matrix as well as cardiac hypertrophy. One of the features of cardiac hypertrophy in hypertension is the increase in extracellular matrix, such as collagen. Of particular importance, overexpression of cardiac ACE stimulates the accumulation of collagen matrix deposition as a typical feature of hypertensive cardiac hypertrophy. Increased cardiac Ang II may contribute to the pathogenesis of cardiac hypertrophy in hypertension through the accumulation of collagen matrix. Cardiac hypertrophy in rats transfected with the human ACE vector might be due to the autocrine/ paracrine effect of locally produced Ang II, since our previous reports demonstrated that locally produced Ang II in cultured vascular smooth muscle cells transfected with the ACE vector increased protein synthesis in an autocrine/ paracrine manner. 18 Alternatively, a decrease in locally produced bradykinin might affect cardiac hypertrophy, as ACE is also a rate-limiting step in the bradykinin pathway. Further studies are necessary to elucidate the role of bradykinin in this cardiac hypertrophy model.
On the other hand, in vivo gene transfer into the heart opens up the possibility of local gene therapy for untreatable cardiac diseases such as myocardial infarction and cardiomyopathy, although existing methods have many limitations, such as low efficiency and/or potential toxicity. Therefore, we have reported the usefulness of the HVJ liposome method for in vivo gene transfer into the intact heart. In the present study, we further tried to modify this method for in vivo gene transfer into the heart by using 2 different approaches: (1) changing promoter construct and (2) modifying the lipid composition of the liposomes. As previously, we reported the high transfection efficiency of the HVJ liposome method. [5] [6] [7] For example, luciferase activity was significantly higher in hearts transfected with luciferase vector by the HVJ liposome method than in hearts transfected by direct injection of "naked" plasmid DNA (HVJ, 187 000Ϯ52 000 light intensity; naked plasmid, 12 000Ϯ2100 light intensity; PϽ0.01). 6 The present study also confirmed the high transfection efficiency of the HVJ liposome method compared with naked DNA transfection. Moreover, our present data also showed significantly high transgene expression with the use of the EBV promoter, as viral chromosomes such as the EBV replicon vector can prolong gene expression. 16 Further usage of the EBV promoter would prolong and enhance transgene expression for long-term experiments. Second, we modified the composition of the liposomes from anionic to cationic (Figure 5a ). Previous studies had reported an increase in transfection efficiency with the use of a cationic HVJliposome complex in in vitro as well as in vivo systems in lung epithelial cells. 16, 19 Unexpectedly, luciferase expression was very low in hearts injected with cationic HVJ liposomes, whereas high luciferase activity was observed by using the conventional HVJ liposomes (anionic type). With the use of FITC-labeled oligodeoxynucleotides, the low transfection efficiency of cationic HVJ liposomes was also confirmed in vivo (M.A. et al, unpublished observation, 1996). The area of transfection was widespread with the HVJ liposome method, as fluorescence could be clearly detected in the upper part of only those hearts transfected by the HVJ liposome method, consistent with previous reports. 7 In contrast, fluorescence was limited to the immediate area around the injection sites when the cationic HVJ liposome complex was used. Moreover, significant myocardial damage with accumulation of neutrophils and necrosis was also observed at the injection site after cationic HVJ liposome injection but not with conventional HVJ liposomes (M.A. et al, unpublished observations, 1996) . Although the present study failed to show the usefulness of a modification of the conventional HVJliposome complex, such modification might be important for developing efficient gene transfer approaches to the heart to further the understanding and treatment of cardiovascular diseases.
Overall, the present findings demonstrate a direct role for the cardiac angiotensin system as a mediator of the cardiac hypertrophy process in hypertension, independent of changes in blood pressure or the endocrine RAS. Moreover, this study of the cardiac angiotensin system serves as a paradigm for the elucidation of the role of other autocrine/paracrine mediators of cardiac remodeling in the pathogenesis of diseases such as myocardial infarction and cardiomyopathy. Our data demonstrate that the localized, in vivo gene transfer technique is a useful experimental tool for the study of autocrine/paracrine factors in complex pathophysiological states in vivo. This approach has broad applicability and is complementary to other methods, such as transgenic technology, in elucidating the biological roles of candidate genes in vivo.
